Status:
TERMINATED
Non-Interventional Study to Evaluate Effect of Zoladex In EndometrioSIS
Lead Sponsor:
AstraZeneca
Conditions:
Endometriosis
Eligibility:
FEMALE
18+ years
Brief Summary
To observe the effect of goserelin 3,6mg sc depot injection by assessment of the mean percent reduction scores for symptoms: dysmenorrhoea, dyspareunia and pelvic pain; to observe the effect of gosere...
Eligibility Criteria
Inclusion
- patients diagnosed with endometriosis that the doctors have already decided to treat with Zoladex within the last month, before inclusion in this program, according to Romanian approved goserelin 3,6 mg
Exclusion
- patients who have a known hypersensitivity to goserelin (Zoladex) or any of its excipients or any other GnRH analogue, pregnancy, according to Romanian approved goserelin 3,6 mg SmPC
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT00761683
Start Date
October 1 2008
Last Update
September 10 2009
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bucharest, Romania
2
Research Site
Cluj-Napoca, Romania
3
Research Site
Timișoara, Romania